The Biologics division of UK company Avecia has launched pAVEway, a
new microbial system for producing high yields of a wide range of
therapeutically active protein, such as vaccines, cytokines and
growth factors.
After receiving a grant of $3.9m (€3m) from the US government,
British biotechnology firm Avecia has put together a consortium of
four companies to develop a version of its anthrax vaccine with
increased stability so it works without...
UK firm Avecia Biotechnology has been given a £1m (€1.5m) grant to
lead a three year project to establish a faster and cheaper
bioprocessing technology for advanced tissue engineering, primarily
to develop new skin to heal burns victims.
Fine and specialty chemicals company Avecia is planning to spin out
part of its pharmaceutical technologies portfolio into a new
company to be called Reaxa. The move should complete before the end
of this quarter.
Avecia Pharmaceuticals has consolidated its position in the
evolving Japanese pharmaceutical market by forging a technology
agreement with a local company,reports Phil Taylor.
UK-based Avecia, Europe's largest privately owned chemicals
company, has teamed up with Germany's IEP to develop new synthetic
routes for pharmaceutical intermediates using biocatalysis.
Avecia has scored a world first with the certification by all
European Union member states of its DNA medicines production
facility at Grangemouth, Scotland.